HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy

Frontiers in Immunology

Immunology

Xin Wan¹  Ou Bai¹  Ken H. Young² 

[1]Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China

[2]Department of Hematopathology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States

关键词: hepatitis B virus;    DLBCL;    epigenetics;    prognosis;    chemo-resistance;   

DOI  :  10.3389/fimmu.2023.1216610

 received in 2023-05-04, accepted in 2023-06-14,  发布年份 2023

来源: Frontiers

【 摘 要 】

Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-line immunochemotherapy regimens, and worse clinical prognosis. HBV-associated DLBCL often exhibits abnormal activation of the nuclear factor kappa B pathway as well as mutations in oncogenes, including Myc and BCL-6. Currently, there is no consensus on any specific and effective treatment for HBV-associated DLBCL. Therefore, in this review, we comprehensively and mechanistically analyzed the natural history of HBV infection and immunity, including HBV-mediated oncogenes, immune escape, epigenetic alterations, dysregulated signaling pathways, and potential therapeutic approaches for HBV-associated DLBCL. We hope that an improved understanding of the biology of HBV-associated DLBCL would lead to the development of novel therapeutic approaches, enhance the number of effective clinical trials, and improve the prognosis of this disease.

【 授权许可】

Unknown   
Copyright © 2023 Wan, Young and Bai